Risk of hepatitis C reinfection among people with current injecting drug use following successful HCV treatment [ 2017 - 2021 ]

Research Grant

Researchers: A/Pr Jason Grebely (Principal investigator) ,  A/Pr Gail Matthews ,  Dr Rowena Bull ,  Dr Tanya Applegate ,  Prof Adrian Dunlop
View all 9 related researchers

Brief description In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs.

Funding Amount $AUD 2,301,360.53

Funding Scheme Project Grants

Notes Standard Project Grant